Mechanism of action
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that selectively inhibits the reuptake of dopamine and norepinephrine in the central nervous system. It has minimal effect on serotonin reuptake, distinguishing it from SSRIs and SNRIs. The exact mechanism by which bupropion exerts its antidepressant and smoking cessation effects is not fully understood, but it is believed to involve enhancement of dopaminergic and noradrenergic neurotransmission.
Bupropion also acts as a noncompetitive antagonist at nicotinic acetylcholine receptors, which contributes to its efficacy in smoking cessation. Its metabolite, hydroxybupropion, is pharmacologically active and contributes to the overall therapeutic effect.
Unlike most antidepressants, bupropion does not cause downregulation of postsynaptic beta-adrenergic receptors with chronic use. The dopaminergic activity is thought to explain why bupropion does not cause sexual dysfunction and may even improve libido and sexual function in some patients.
- Bupropion inhibits dopamine and norepinephrine reuptake; it does NOT affect serotonin.
- Most serious adverse effect is dose-dependent seizures; contraindicated in seizure disorders and eating disorders.
- Does NOT cause sexual dysfunction or weight gain, unlike SSRIs; may cause modest weight loss.
- FDA-approved for major depression, smoking cessation, and seasonal affective disorder.
- Absolute contraindication in anorexia nervosa and bulimia nervosa due to increased seizure risk.
- Inhibits CYP2D6, increasing levels of beta-blockers, antipsychotics, and reducing tamoxifen and codeine efficacy.
- Can precipitate mania in bipolar disorder; screen patients before initiating treatment.
- Common side effects include insomnia, agitation, dry mouth, and tremor (dopaminergic/noradrenergic effects).
Indications
Bupropion is FDA-approved for the following indications:
- Major depressive disorder (MDD): Used as monotherapy or adjunct to other antidepressants. Particularly useful in patients who have not responded to SSRIs or who experience SSRI-induced sexual dysfunction.
- Smoking cessation: Marketed as Zyban for this indication. It reduces nicotine cravings and withdrawal symptoms.
- Seasonal affective disorder (SAD): Extended-release formulation is approved for prevention of seasonal major depressive episodes in patients with SAD.
Off-label uses
- Attention-deficit/hyperactivity disorder (ADHD) in adults
- Weight loss (combination product with naltrexone is FDA-approved for weight management)
- Augmentation strategy in treatment-resistant depression
- Cocaine and methamphetamine dependence (limited evidence)
Bupropion is often chosen when sexual dysfunction and weight gain are concerns, as it does not typically cause these side effects and may even promote modest weight loss.
Pharmacokinetics
Absorption: Bupropion is well absorbed from the gastrointestinal tract. Peak plasma concentrations occur approximately 2 hours after immediate-release formulation and 3 hours after sustained-release formulation. Extended-release formulations allow once-daily dosing.
Distribution: Bupropion is approximately 84% protein-bound. It distributes widely into tissues including the brain.
Metabolism: Extensively metabolized in the liver primarily by CYP2B6 to three active metabolites: hydroxybupropion, threohydrobupropion, and erythrohydrobupropion. Hydroxybupropion is the major active metabolite and has a longer half-life than the parent compound. Bupropion is a CYP2D6 inhibitor, which can lead to drug interactions.
Elimination: The elimination half-life of bupropion is approximately 21 hours for the extended-release formulation. Metabolites are excreted primarily in urine (87%) and feces (10%). Dose adjustment is recommended in patients with hepatic or renal impairment.
Formulations: Available as immediate-release (IR), sustained-release (SR), and extended-release (XL) formulations. The XL formulation is preferred for once-daily dosing and has a lower seizure risk compared to IR formulation.
Adverse effects
Common adverse effects
- Insomnia: Most common side effect, occurs in up to 40% of patients. Taking the medication earlier in the day may help.
- Dry mouth: Very common, managed with sugar-free gum or candy.
- Nausea: Usually transient and improves with continued use.
- Headache: Common, often resolves spontaneously.
- Tremor and agitation: Dose-dependent dopaminergic effects.
- Weight loss: Modest weight loss (average 2-3 kg) is common, unlike other antidepressants.
- Tachycardia and hypertension: Due to noradrenergic effects.
Serious adverse effects
- Seizures: The most serious adverse effect. Risk is dose-dependent, approximately 0.1% at doses ≤300 mg/day and 0.4% at doses of 300-450 mg/day. Risk increases significantly above 450 mg/day. Contraindicated in patients with seizure disorders, eating disorders (anorexia/bulimia), or abrupt discontinuation of alcohol or benzodiazepines.
- Neuropsychiatric symptoms: Agitation, psychosis, hallucinations, paranoia, delusions, and mood changes have been reported, particularly during smoking cessation.
- Suicidal ideation: Like all antidepressants, carries a black box warning for increased risk of suicidal thoughts and behavior in children, adolescents, and young adults up to age 24.
- Hypertension: Can cause or exacerbate hypertension; blood pressure should be monitored.
- Activation of mania/hypomania: Can precipitate manic episodes in patients with bipolar disorder.
- Allergic reactions: Rare but can include Stevens-Johnson syndrome, angioedema, and anaphylaxis.
Advantages over other antidepressants
Bupropion does not typically cause sexual dysfunction, weight gain, or sedation, which are common with SSRIs and other antidepressants. This makes it a preferred choice in patients concerned about these side effects.
Contraindications and warnings
Absolute contraindications
- Seizure disorder: Current or prior history of seizures.
- Eating disorders: Anorexia nervosa or bulimia nervosa (increased seizure risk due to electrolyte disturbances).
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs: Increases seizure risk.
- Use of MAO inhibitors: Must wait at least 14 days after discontinuing an MAOI before starting bupropion.
- Hypersensitivity: Known allergy to bupropion or any component of the formulation.
Warnings and precautions
- Bipolar disorder: Screen patients for bipolar disorder before initiating treatment, as bupropion can precipitate manic episodes. Use with caution or consider mood stabilizer coadministration.
- Hepatic impairment: Use with caution and reduce dose in patients with hepatic cirrhosis.
- Renal impairment: Dose reduction recommended in severe renal impairment.
- Cardiovascular disease: Monitor blood pressure and heart rate, as bupropion can increase both.
- Psychosis: Can exacerbate psychotic symptoms in patients with schizophrenia or other psychotic disorders.
- Pregnancy: Category C. Limited human data; use only if benefits outweigh risks. Present in breast milk.
- Angle-closure glaucoma: Mydriasis has been reported; use with caution in patients at risk.
Black box warning
Bupropion carries a black box warning for suicidal thoughts and behaviors in children, adolescents, and young adults (age 24 and younger) during initial treatment, typically within the first few months. Close monitoring is required, especially during dose changes.
Drug interactions
Major interactions
- MAO inhibitors: Concurrent use is contraindicated due to risk of hypertensive crisis. Allow 14 days washout period.
- CYP2D6 substrates: Bupropion inhibits CYP2D6, increasing levels of drugs metabolized by this enzyme, including metoprolol, carvedilol, codeine (reducing its analgesic effect), tamoxifen (reducing active metabolite formation), and many antipsychotics and antidepressants.
- Drugs that lower seizure threshold: Antipsychotics, other antidepressants, theophylline, systemic corticosteroids, tramadol, quinolone antibiotics, and stimulants increase seizure risk.
- Alcohol: Increases seizure risk, especially with heavy use or during withdrawal.
- Ritonavir and other CYP2B6 inhibitors: Increase bupropion levels; dose reduction may be necessary.
- Carbamazepine, phenytoin, phenobarbital: CYP2B6 inducers decrease bupropion levels; dose increase may be necessary.
Moderate interactions
- Levodopa and amantadine: Concurrent use increases risk of neuropsychiatric adverse effects; start with low doses and monitor closely.
- Nicotine replacement therapy: Can be used together for smoking cessation but may increase blood pressure.
- Dopaminergic drugs: Additive dopaminergic effects may increase risk of adverse effects.
Pharmacodynamic considerations
Bupropion's effects on dopamine and norepinephrine can interact with other drugs affecting these neurotransmitter systems, including stimulants, sympathomimetics, and dopamine agonists.
Clinical pearls
- Think dopamine and norepinephrine, not serotonin: Bupropion is unique among antidepressants for its lack of serotonergic activity, making it useful when SSRIs cause sexual dysfunction or weight gain.
- Seizure risk is dose-dependent: The immediate-release formulation has the highest seizure risk. Always use sustained-release or extended-release formulations and avoid exceeding 450 mg/day total dose (or 200 mg single dose for SR formulation).
- Ideal for smoking cessation with comorbid depression: Addresses both conditions simultaneously. Start 1-2 weeks before the target quit date.
- No sexual dysfunction: Unlike SSRIs, bupropion does not cause sexual side effects and may actually improve libido. Often added to SSRIs to counteract SSRI-induced sexual dysfunction.
- Weight loss, not gain: Causes modest weight loss, making it attractive for patients concerned about weight gain from other antidepressants.
- Screen for eating disorders and seizures: Always ask about history of anorexia, bulimia, or seizures before prescribing—absolute contraindications.
- Activating, not sedating: Take in the morning or early afternoon to avoid insomnia. The stimulating properties can be beneficial in patients with fatigue and low energy.
- Bipolar disorder risk: Can induce mania; always screen for personal or family history of bipolar disorder before initiating treatment.
- CYP2D6 inhibition matters: Be alert for interactions with beta-blockers, antipsychotics, and tamoxifen. Bupropion can reduce the efficacy of codeine and tamoxifen by inhibiting their conversion to active metabolites.
- Pregnancy and lactation: Limited data; generally avoided in pregnancy unless benefits clearly outweigh risks. Present in breast milk.
- Combination therapy: Often combined with SSRIs or mirtazapine in treatment-resistant depression, providing complementary mechanisms of action.
Bupropion Seizures: BANNED — Bulimia, Anorexia, Neurologic disorder (seizure), Neurotoxic drugs, Ethanol withdrawal, Dose >450 mg/day
Practice questions
1. A 32-year-old woman presents to her psychiatrist for follow-up of major depressive disorder. She has been taking sertraline 100 mg daily for 6 months with good response in terms of mood, but she complains of anorgasmia and decreased libido. She is otherwise healthy and takes no other medications. Her psychiatrist decides to switch her to a different antidepressant. Which of the following is the most appropriate alternative?
2. A 28-year-old man with no significant past medical history presents to establish care and requests pharmacotherapy for smoking cessation. During the interview, he mentions that he had two seizures as a teenager following a head injury from a motor vehicle accident but has been seizure-free for 10 years without medication. Which of the following is the most appropriate pharmacotherapy for this patient?
3. A 45-year-old woman with a 2-year history of major depressive disorder on bupropion 300 mg daily presents to the emergency department with agitation, pressured speech, decreased need for sleep, and grandiose delusions that started 3 days ago. Her husband reports she has been extremely productive, started multiple new projects, and has been spending money impulsively. She has no history of substance abuse. On examination, she is talkative, distractible, and has flight of ideas. Which of the following best explains this patient's presentation?
Frequently asked questions
How does bupropion work?
Bupropion works by inhibiting the reuptake of dopamine and norepinephrine in the brain, increasing the availability of these neurotransmitters. Unlike most antidepressants, it does not affect serotonin. It also acts as a noncompetitive antagonist at nicotinic acetylcholine receptors, which contributes to its effectiveness in smoking cessation. The exact mechanism for its antidepressant effect is not fully understood but is thought to involve enhanced dopaminergic and noradrenergic neurotransmission.
What are the side effects of bupropion?
Common side effects include insomnia, dry mouth, nausea, headache, tremor, and agitation. Bupropion typically causes weight loss rather than weight gain and does not cause sexual dysfunction, unlike SSRIs. The most serious adverse effect is seizures, which are dose-dependent and occur in approximately 0.4% of patients at therapeutic doses. Other serious effects include hypertension, activation of mania in bipolar disorder, and neuropsychiatric symptoms such as agitation and psychosis. It carries a black box warning for increased suicidal thoughts in young adults.
Is bupropion a controlled substance?
No, bupropion is not a controlled substance by the DEA. However, there have been rare reports of abuse and dependence, particularly at high doses, likely related to its dopaminergic effects. Some individuals have attempted to misuse bupropion by crushing and snorting tablets to achieve stimulant-like effects, but this practice is dangerous and increases seizure risk substantially. Despite these isolated cases, bupropion has low abuse potential compared to true stimulants and is not classified as a controlled substance.
Bupropion vs sertraline — what is the difference?
Bupropion and sertraline are both antidepressants but work through different mechanisms. Bupropion inhibits dopamine and norepinephrine reuptake (NDRI) and does not affect serotonin, while sertraline is a selective serotonin reuptake inhibitor (SSRI). Bupropion does not cause sexual dysfunction or weight gain and may actually promote weight loss, whereas sertraline commonly causes sexual side effects and weight gain. Bupropion is more activating and can cause insomnia, while sertraline can be sedating in some patients. Bupropion is contraindicated in seizure disorders, whereas sertraline is not. Both are effective for depression, but bupropion is also approved for smoking cessation.
Can bupropion cause weight gain?
No, bupropion typically does not cause weight gain; in fact, it usually causes modest weight loss. This is one of the key advantages of bupropion over other antidepressants like SSRIs, SNRIs, mirtazapine, and tricyclic antidepressants, which commonly cause weight gain. Clinical trials show an average weight loss of 2-3 kg over several months of treatment. The mechanism is not fully understood but may involve dopaminergic effects on appetite and metabolism. A combination product of bupropion with naltrexone (Contrave) is FDA-approved specifically for weight management in obese patients.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06AX12
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.